Better Deep Sleep Under More Stress

01Introduction

1.1 The Expected Direction

Psychosocial stress activates the HPA axis, elevates evening cortisol, and increases sympathetic tone during sleep — all of which directly suppress SWS and reduce restorative sleep fraction (Buckley & Schatzberg, 2005; Leproult et al., 1997). A morning-chronotype individual forced into late sleep schedules under significant occupational pressure faces the compounded disruption of two established mechanisms simultaneously (Roenneberg et al., 2012). The expected clinical picture is shorter SWS, lower sleep efficiency, fragmented nights, and accumulating sleep debt.

1.2 The Paradox

This case documents the opposite. During the highest-demand professional period in 840 nights of continuous tracking, with shorter sleep opportunity and later bedtimes than the subject's biology preferred, deep and restorative sleep reached its best recorded values. Two independent wearable devices, worn simultaneously, agreed on this finding.

02Methods

2.1 Subject

Female physician, 54 years (MD, PhD), cardiologist, active clinical and research practice. Morning chronotype confirmed by Oura Ring continuous algorithm: biological chronotype Morning, currently lifestyle-displaced to Early Evening. Oura Sleep Timing contributor averaged 99/100 across the measurement window — internal clock maintaining phase despite behavioural displacement. Perimenopausal throughout. Foundational supplements maintained unchanged throughout all phases: omega-3 fatty acids, creatine monohydrate, vitamin D3/K2, methylated B-complex.

2.2 Dual-Device Measurement

Table 1. Dual-device specifications. Independent proprietary algorithms, different sensor wavelengths, different anatomical placements. Both devices worn simultaneously throughout all 840 nights.

2.3 Four Sequential Phases

Table 2. Four sequential phases. Supplement composition during Phases 0–1 was not prospectively recorded; stated as a limitation. Full EscapeMed 30D formulation published in companion paper (Samarin, 2026).

2.4 Genomic Profile

Whole-genome sequencing: Dante Labs, April 2024 (Kit ID GFX0455821). Two categories of variants are reported: (A) sleep and protocol-relevant variants from the clinical Dante Labs report; (B) pharmacogenomic and autonomic variants identified by targeted VCF analysis using chromosomal position search.

Table 3. Complete genomic profile. GRK5 and ADRB2 identified by targeted VCF position search; clinical significance for HRV is biologically plausible but not definitively established in published HRV GWAS literature.

2.5 Primary Outcomes

WHOOP: SWS duration (min/night), Restorative Sleep % (Deep+REM / time in bed), Sleep Efficiency %, Sleep Consistency %. Oura: Sleep Score, Deep Sleep contributor, Timing contributor, Sleep Efficiency %. Composite outcome: High-quality night = Restorative% ≥50% AND Efficiency ≥93% simultaneously on WHOOP.

03Results

3.1 Four-Phase Progression

Table 4. Primary WHOOP outcomes across four phases. High-quality night = Restorative% ≥50% AND Efficiency ≥93% simultaneously. Phase 2 SWS slightly lower than Phase 1, consistent with seasonal variation (Jun–Aug 2025). Phase 3 highlighted: highest demand, best results.

Figure 1

Four-Phase Sleep Architecture Progression — WHOOP 840 Nights. SWS min/night (blue, left axis) and Restorative % (gold, right axis) with 30-day rolling average. Four vertical markers indicate phase transitions. Both metrics show consistent progressive improvement, with Phase 3 recording the best values despite highest professional demand and shortest time in bed.

3.2 The Single Largest Step Change: February → March 2025

The transition from unstructured supplementation to the first timed formula produced the largest single measurable change in 840 nights:

Table 5. February vs March 2025: the Super Sleep transition — the largest single step change in the 840-night dataset.

3.3 Phase 3: Best Sleep During Worst Conditions

Phase 3 (January 27 – April 24, 2026) coincided with the highest occupational pressure, latest bedtimes, and shortest time in bed (−36.7 min/night vs baseline) in the 840-night record. Despite this:

• High-quality nights: 15.2% in Phase 2 → 33.3% in Phase 3 — frequency doubled with the addition of Magnesium AM and PM
• 8 of the top 15 SWS nights in 840 nights occurred during the 88-day Phase 3 window — 10% of total nights produced 53% of the top-15 SWS nights
• Phase 3 vs the equivalent preceding 88 days: SWS +5.8 min, REM +4.6 min, Restorative% +3.7 points — improvement sustained despite higher demand and less time in bed
• The magnitude of improvement exceeded the subject's own expectation given concurrent lifestyle conditions — consistent with an effect not primarily driven by expectation or placebo

3.4 Oura Ring: Independent Corroboration

Table 6. Oura Ring Phase 3 metrics. Oura assessment generated without knowledge of supplement protocol.

3.5 Genomic Context for the Autonomic Phenotype

The subject reports chronically low HRV across the full 840-night tracking period, inconsistent with lifestyle or perimenopausal explanation alone. Targeted VCF analysis identified two variants in the beta-adrenergic signalling pathway: GRK5 rs10886471 (homozygous) — G-protein coupled receptor kinase 5 associated with increased GRK5 expression, faster adrenergic receptor desensitisation, and a plausible structural basis for a constitutionally lower HRV ceiling. ADRB2 rs1042713 Arg16Gly (heterozygous) — beta-2 adrenergic receptor variant associated with lower HRV sympathetic indices in Arg16 carriers.

These findings suggest the subject's low HRV baseline may have a partial constitutional genetic explanation. The protocol's sleep architecture improvements are even more remarkable given the constrained autonomic substrate. A dedicated analysis of 840 nights of HRV data in the context of these variants is planned as a separate report.

Figure 2

Figure 2. Genomic Profile — Why This Protocol Fits This Individual. Five variants of mechanistic relevance identified by whole-genome sequencing (Dante Labs, April 2024). Each variant provides individualised biological rationale for a specific architectural feature of the EscapeMed 30D protocol. GRK5 and ADRB2 are reported in the context of the autonomic phenotype (Section 3.5) and are not included in this figure.

3.6 Early Adaptation Signature — Day 5 Power Nap

February 1, 2026 (Phase 3 Day 5): spontaneous afternoon power nap, WHOOP staging:

Table 7. Power nap staging, February 1 2026 (Phase 3 Day 5). REM sleep during a daytime nap is atypical and consistent with the early adaptation signature described in the companion protocol paper: glycine-driven REM density increase and circadian resynchronisation during Days 3–5.

Figure 4

Figure 4. Early Adaptation Signature — Day 5 Power Nap. February 1, 2026 — Afternoon Power Nap — WHOOP 4.0. Sleep staging: 21% Light, 59% Deep SWS, 20% REM, <1% Awake. Efficiency 100%. REM during a daytime nap is rare and consistent with the circadian resynchronisation signature documented in the companion EscapeMed 30D grand review paper.

Figure 3 — Both Devices · All Four Phases

Figure 3. Four-phase comparison — WHOOP + Oura Ring. Same ingredients. Better timing. Better sleep. Phase 3 (Full Protocol, n=84 nights, amber highlight) records the best values on all primary metrics across both independent devices. Blue: SWS hours/night · Orange: Restorative % · Green: Sleep Efficiency % · Purple: High-quality nights % · Red: Oura Deep Sleep contributor.

04Discussion: Explaining the Paradox

4.1 The Paradox Resolves When the Target Is Understood

Stress suppresses deep sleep through specific, well-characterised biological mechanisms: elevated evening cortisol suppresses SWS directly; increased sympathetic activation during sleep fragments sleep architecture; circadian disruption from late schedules reduces SWS amplitude. The protocol did not reduce stress. It targeted each of these three mechanisms independently and simultaneously.

4.2 Architecture Was the Primary Variable

The largest single improvement in 840 nights occurred not when new ingredients appeared, but when timing discipline was first imposed on existing ones. The CLOCK/BMAL1 molecular clock regulates an estimated 40–80% of protein-coding genes (Takahashi, 2017). A melatonin signal at the correct phase entrains the SCN; the same molecule randomly timed produces sedation without entrainment. A magnesium dose at the evening GABA-A window amplifies inhibitory transmission; the same dose at noon does not. Architecture is not supplementary to the ingredient — it determines what the ingredient does.

4.3 The Genomic Layer: Why This Individual Responded

• CYP1A2 HET: Makes the 0.20mg melatonin dose not just philosophically elegant but pharmacogenomically necessary. This subject cannot use standard commercial melatonin products effectively.
• ESR1 C/C: Makes dual-formula magnesium repletion an individualised necessity, not a general recommendation.
• NQO1 HET Likely Pathogenic: Reduced endogenous antioxidant capacity means the 24-hour anti-inflammatory arc is compensating for a genetically reduced baseline.
• MTHFR HET: Makes P5P (active B6) not a preference but a mechanistic requirement for melatonin synthesis efficiency in this individual.
• GRK5 HOM + ADRB2 HET: Provide a constitutional genetic explanation for chronically low HRV that is independent of the sleep findings, and contextualise why Recovery scores from both wearables should be interpreted against a personally adjusted baseline.

05Limitations

• N=1; no control condition; no randomisation; causal inference not possible
• Supplement composition during Phases 0 and 1 not prospectively recorded; cannot be fully reconstructed
• Three variables changed simultaneously at Phase 0→1: timing architecture, stack reduction, and physical condition
• Both wearables use proprietary algorithms; cross-device agreement does not equal polysomnographic accuracy
• Hormonal status (estradiol, progesterone) not measured; perimenopausal fluctuations are a known sleep confounder
• GRK5 and ADRB2 HRV associations are biologically plausible but not definitively established in published HRV GWAS literature
• Seasonal variation in SWS may partially confound Phase 2 metrics
• Subject is protocol formulator and company founder; conflict of interest is substantial and fully disclosed

06Conclusions

Across 840 nights of continuous simultaneous dual-device monitoring, progressive reorganisation of an unstructured supplement stack into a four-formula chronobiologically timed system produced stepwise improvement in deep and restorative sleep architecture at each phase transition — with the best sleep recorded during the most demanding professional period in the dataset.

The paradox — better deep sleep under more stress — resolves when the mechanism is understood: the protocol did not reduce stress, it blocked the three specific pathways by which stress translates into poor sleep architecture. Each mechanism is individually justified by the subject's genomic profile, making this not a generic supplement programme but a precision chronobiological intervention matched to her specific biological vulnerabilities.

The primary variable was timing discipline: the largest single improvement in 840 nights occurred when the first timed formula was introduced — despite many of the same core ingredients being already present. Controlled investigation in adequately powered cohorts is warranted.